ArticleJAMA oncology2023
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer.
Article in JAMA oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01150045 (A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Who cites it
35 citing papers in PubMed, 40 citations in OpenAlex.
- Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.JAMA oncology · 2026Trial
- Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer.Cancer · 2025Trial
- Effect of preoperative oral carbohydrate combined with postoperative early enteral nutrition on the perioperative rehabilitation of patients with colorectal cancer: a multicenter randomized controlled trial.Frontiers in nutrition · 2025Trial
- Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance).Journal of the National Cancer Institute · 2024Trial
- Exercise as a Disease-Modifying Therapy in Colon Cancer: Practice-Changing Evidence from the CHALLENGE Trial.Cancers · 2026Review
- Dietary fat, inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer survivors: An exploratory cross-sectional study.Journal of the Academy of Nutrition and Dietetics · 2026Article
- Retinal Vascular Features and Risk of Colorectal Cancer Incidence and Mortality: A Population-Based Cohort Study.Ophthalmology and therapy · 2026Article
- Anti-inflammatory Diet Before Diagnosis and Survival After Urologic Cancer: Findings from Two Swedish Prospective Cohorts.European urology open science · 2026Article
- Systemic Protein Biomarkers, Composite Blood Inflammatory Indices and Cellular Ratios in Metastatic Colorectal Cancer: Potential Therapeutic Targets.Diseases (Basel, Switzerland) · 2026Article
- Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.Cancer medicine · 2026Article
- The Predictive Value of Clinical and Systemic Inflammatory Biomarkers in Emergency Colic Cancer Surgery: A Retrospective Study.Journal of clinical medicine · 2026Article
- Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care.Nature reviews. Clinical oncology · 2025Article
- Predictive value of systemic immune-inflammation index and serum lactoferrin for postoperative survival in older patients with colon cancer.World journal of gastrointestinal surgery · 2025Article
- Review
- Gut commensal bacteria influence colorectal cancer development by modulating immune response in AOM/DSS-treated mice.Microbiology spectrum · 2025Article
- Tumor Necrosis Factor-Alpha's Role in the Pathophysiology of Colon Cancer.Diseases (Basel, Switzerland) · 2025Review
- Plant-based diet, inflammation biomarkers and body composition among women with breast cancer: the Pathways Study.The British journal of nutrition · 2025Article
- Cancer-Specific RNA Modifications in Tumour-Derived Extracellular Vesicles Promote Tumour Growth.Journal of extracellular vesicles · 2025Article
- Early recovery of leukocyte subsets is associated with favorable progression-free survival in patients with inoperable stage II/III NSCLC after multimodal treatment: a prospective explorative study.Radiation oncology (London, England) · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 15 institutions in 2 countries.
Funding
Abstract
Importance: The association of chronic inflammation with colorectal cancer recurrence and death is not well understood, and data from large well-designed prospective cohorts are limited. Objective: To assess the associations of inflammatory biomarkers with survival among patients with stage III colon cancer. Design, Setting, and Participants: This cohort study was derived from a National Cancer Institute-sponsored adjuvant chemotherapy trial Cancer and Leukemia Group B/Southwest Oncology Group 80702 (CALGB/SWOG 80702) conducted between June 22, 2010, and November 20, 2015, with follow-up ending on August 10, 2020. A total of 1494 patients with plasma samples available for inflammatory biomarker assays were included. Data were analyzed from July 29, 2021, to February 27, 2022. Exposures: Plasma inflammatory biomarkers (interleukin 6 [IL-6], soluble tumor necrosis factor α receptor 2 [sTNF-αR2], and high-sensitivity C-reactive protein [hsCRP]; quintiles) that were assayed 3 to 8 weeks after surgery but before chemotherapy randomization. Main Outcomes and Measures: The primary outcome was disease-free survival, defined as time from randomization to colon cancer recurrence or death from any cause. Secondary outcomes were recurrence-free survival and overall survival. Hazard ratios for the associations of inflammatory biomarkers and survival were estimated via Cox proportional hazards regression. Results: Of 1494 patients (median follow-up, 5.9 years [IQR, 4.7-6.1 years]), the median age was 61.3 years (IQR, 54.0-68.8 years), 828 (55.4%) were male, and 327 recurrences, 244 deaths, and 387 events for disease-free survival were observed. Plasma samples were collected at a median of 6.9 weeks (IQR, 5.6-8.1 weeks) after surgery. The median plasma concentration was 3.8 pg/mL (IQR, 2.3-6.2 pg/mL) for IL-6, 2.9 × 103 pg/mL (IQR, 2.3-3.6 × 103 pg/mL) for sTNF-αR2, and 2.6 mg/L (IQR, 1.2-5.6 mg/L) for hsCRP. Compared with patients in the lowest quintile of inflammation, patients in the highest quintile of inflammation had a significantly increased risk of recurrence or death (adjusted hazard ratios for IL-6: 1.52 [95% CI, 1.07-2.14]; P = .01 for trend; for sTNF-αR2: 1.77 [95% CI, 1.23-2.55]; P < .001 for trend; and for hsCRP: 1.65 [95% CI, 1.17-2.34]; P = .006 for trend). Additionally, a significant interaction was not observed between inflammatory biomarkers and celecoxib intervention for disease-free survival. Similar results were observed for recurrence-free survival and overall survival. Conclusions and Relevance: This cohort study found that higher inflammation after diagnosis was significantly associated with worse survival outcomes among patients with stage III colon cancer. This finding warrants further investigation to evaluate whether anti-inflammatory interventions may improve colon cancer outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT01150045.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.